Alcidion Delivering ‘Software as a Medical Device’ AI Capabilities in Both Australia and the UK

Key Takeaways

• Concept Detection now ARTG and MHRA Class 1 certified
• AI suggests SNOMED CT codes from clinicians’ free‑text notes
• Clinician validation required before adding concepts to records
• Certification enables commercial rollout across Australia and UK
• Miya AI Service supports secure, scalable AI deployment

Pulse Analysis

The rise of Software as a Medical Device (SaMD) has reshaped how health technology firms approach compliance. In Australia and the United Kingdom, regulators demand rigorous safety and performance evidence before AI tools can be used in patient care. By securing Class 1 registration on both the ARTG and MHRA, Alcidion demonstrates that its AI module meets these stringent standards, offering health organisations a trusted solution that aligns with emerging digital health policies.

Concept Detection, embedded within the Miya Precision platform, leverages natural‑language processing to translate free‑text clinical notes into structured SNOMED CT terminology. This automation reduces the time clinicians spend searching for appropriate codes, cuts documentation errors, and enhances data quality for downstream analytics. Crucially, the system retains a human‑in‑the‑loop model: clinicians must review and approve each suggested concept, preserving clinical judgment while easing cognitive load.

For the market, Alcidion’s dual‑market certification unlocks rapid scaling across its existing customer base and new health systems seeking compliant AI tools. The accompanying Miya AI Service provides a secure, modular architecture that can host future AI capabilities, positioning the company as a scalable SaMD provider. As hospitals worldwide tighten requirements for certified AI, Alcidion’s regulatory foothold gives it a competitive edge and signals broader industry momentum toward AI‑enabled, standards‑compliant clinical workflows.